
Axsome Therapeutics Inc (NASDAQ:AXSM) shares are trading higher Monday after the company reported it was informed by the U.S. Food and Drug Administration (FDA) that chemistry, manufacturing and control issues identified during the FDA's review of its New Drug Application for its AXS-07 product candidate are unresolved.
Axsome Therapeutics is a biopharmaceutical company developing novel therapies for central nervous system conditions that have limited treatment options.